Loading
A phase 2 trial of Carboplatin, Mirvetuximab soravtansine, Bevacizumab in ovarian cancer, run by AbbVie, now recruiting.
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. is a phase 2 interventional study registered as NCT06890338 by AbbVie, with 140 participants planned, started 2025-11-21 and due to reach its primary completion in 2030-02. Interventions recorded: Carboplatin, Mirvetuximab Soravtansine, Bevacizumab. Conditions listed: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant. No results are recorded here; the registry entry is the source.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Carboplatin.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Platinum agents, Carboplatin.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Carboplatin, Ovarian cancer.
Shares Mirvetuximab soravtansine, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Mirvetuximab soravtansine, Carboplatin, Antibody-drug conjugate (ADC), Ovarian cancer.